385TiP AZD0901 monotherapy in patients (pts) with advanced biliary tract cancer (BTC) expressing claudin18.2 (CLDN18.2): CLARITY-PanTumour01 substudy 3
Love Goyal(The Christie NHS Foundation Trust), Ali Raufi(Brown University), Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Laura Barker(AstraZeneca (Singapore)), P. Szekeres(AstraZeneca (Netherlands)), Florian Castet(Institut d'Investigació Biomédica de Bellvitge), Kenneth S. Thress(AstraZeneca (United States)), K. Shitara(National Cancer Center Hospital East), José Eduardo Martinez(AstraZeneca (Netherlands)), E. Elimova(Princess Margaret Cancer Centre), Marcella Petrone(AstraZeneca (United Kingdom)), Makoto Origuchi(AstraZeneca (South Korea)), Giovanni Galletti(AstraZeneca (Netherlands)), D-Y. Oh(Seoul National University Hospital)
Cited by 1
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2016|843